Revenue Update on DURECT Corporation(NASDAQ:DRRX)

DURECT Corporation(NASDAQ:DRRX) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 1, 2016. Company reported revenue of $3.16M. Analysts estimated a revenue of $3.69M. Earnings per share were $-0.07. Analysts had estimated an EPS of $-0.06.

DURECT Corporation (DRRX) shares turned negative on Mondays trading session with the shares closing down -0.07 points or -3.72% at a volume of 5,12,709. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $1.86. The peak price level was also seen at $1.86 while the days lowest was $1.785. Finally the shares closed at $1.81. The 52-week high of the shares is $2.71 while the 52-week low is $0.99. According to the latest information available, the market cap of the company is $249 M.

Several Insider Transactions has been reported to the SEC. On Apr 28, 2016, Felix Theeuwes (Chairman and CSO) purchased 160,000 shares at $1.25 per share price.Also, On Apr 28, 2016, Dave Hoffmann (director) purchased 200,000 shares at $1.25 per share price.On Mar 16, 2016, Terrence F Blaschke (director) purchased 3,000 shares at $1.35 per share price, according to the Form-4 filing with the securities and exchange commission.

Durect Corporation is a specialty pharmaceutical company. The Company is focused on the development of pharmaceuticals based on its drug delivery technology platforms chemical entities derived from its Epigenomic Regulator Program and its engagement in drug development. Its research and development programs fall into one of two categories: Drug Delivery Programs in which it applies its formulation and technologies to pharmaceutical ingredients and New Chemical Entities derived from its Epigenomic Regulator Program in which it discovers and develops molecules. It also manufactures and sells osmotic pumps and biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products. Its product pipeline consists of seven investigational drug candidates in clinical development: REMOXY (ORADUR-Oxycodone) POSIDUR (SABER-Bupivacaine) ELADUR (TRANSDUR-Bupivacaine) Relday ORADUR-ADHD ORADUR-Opioid and SABER-based ophthalmic.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

DURECT Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on DURECT Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.